[Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].

Huang, H J; Shi, Z X; Li, B; Qin, T J; Xu, Z F; Zhang, H L; Fang, L W; Hu, N B; Pan, L J; Qu, S Q; Liu, D; Cai, Y N; Zhang, Y D; Xiao, Z J

Huang, H J; Shi, Z X; Li, B; Qin, T J; Xu, Z F; Zhang, H L; Fang, L W; Hu, N B; Pan, L J; Qu, S Q; Liu, D; Cai, Y N; Zhang, Y D; Xiao, Z J.

Affiliation

Huang HJ; Institute of Hematology and Blood Diseases Hospital CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

Zhonghua Xue Ye Xue Za Zhi ; 40(3): 215-221, 2019 Mar 14.

Article in Zh | MEDLINE | ID: mdl-30929389

Subject(s)

Genes, p53; Myelodysplastic Syndromes; Adolescent; Adult; Aged; Aged, 80 and over; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Myelodysplastic Syndromes/genetics; Prognosis; Tumor Suppressor Protein p53; Young Adult

Key words

Deletion; Mutation; Myelodysplastic syndromes; Prognosis; TP53 gene

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Genes, p53 Type of study: Prognostic_studies Limits: Adolescent / Adult / Aged / Aged80 / Humans / Middle aged Language: Zh Journal: Zhonghua Xue Ye Xue Za Zhi Year: 2019 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google